Microneutralization reaction compared to hemagglutination inhibition assay to evaluate immunogenicity of influenza vaccines and influenza diagnostics

Cover Page


Cite item

Full Text

Abstract

The aim of this study was to compare the results of the hemagglutination inhibition test (HI-test) and microneutralization reaction in detection of antibodies to influenza A(H1N1), A(H1N1)pdm09, and A(H3N2) viruses in human sera, as well optimize microneutralization reaction conditions. The proposed variant of microneutralization reaction is based on detecting decreased influenza virus reproduction in infected MDCK cells in the presence of virus-specific serum antibodies. Virus reproduction was evaluated by enzyme-linked immunosorbent assay in 96-well cell culture plates using type-specific anti-influenza A viruse NP-protein monoclonal antibodies. In parallel, in microneutralization reaction and HI-test paired sera collected from 205 volunteers inoculated with inactivated seasonal influenza vaccines were analyzed, as well as from 117 adult patients with laboratory-confirmed influenza. The rationale for treatment of human serum with receptor-destroying enzyme (RDE) was proved not only for HI-test, but also for microneutralization reaction. Compared to HI-assay, the microneutralization reaction displayed higher sensitivity. According to microneutralization data, seroconversion rates and increase in antibody titer against influenza A viruses in both vaccinated and infected persons were superior to HI-test data by 1.4–2.5-fold. Moreover, higher sensitivity of this method was of great importance for the diagnostics of disease caused by new pathogens. The efficacy of influenza A(H1N1)pdm09 serodiagnostics in PCRpositive patients was 1.5 times higher based on microneutralization reaction vs. HI-assay data. According to the data from early studies, it is commonly believed that 1/40 titer of flu-specific antibodies detected by HI-test is set as protective. However, a consensus on protective level for virus-specific antibodies in neutralization reaction has not been established yet. It was found that serum antibody levels detected by the proposed version of microneutralization reaction were significantly higher than those in HI-assay. In the post vaccination sera collected from vaccinated volunteers, average titers of virus neutralizing antibodies corresponding to 1/40 in HI-test were 1/195, 1/203, and 1/ 426–1/430 for influenza A(H1N1), A(H1N1)pdm09 and A(H3N2), respectively, whereas in influenza patients they were 1/285, 1/215 and 1/488, respectively. Thus, it was suggested to consider a threshold value for “conditionally protective” level of neutralizing antibodies in adult vaccinated volunteers or infected patients, an average titer 1/160 for A(H1N1) and A(H1N1)pdm09 viruses, as well as 1/320 — for A(H3N2) virus, which agree with data published elsewhere.

About the authors

V. Z. Krivitskaya

Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation

Author for correspondence.
Email: vera.kriv@influenza.spb.ru

Vera Z. Krivitskaya, PhD, MD (Biology), Leading Researcher, Laboratory for the Study of Risk Factors for Influenza and ARVI

197376, St. Petersburg, Professor Popov str., 15/17.

Phone/fax: +7 (812) 499-15-29 (office); +7 921 886-37-95 (mobile).

Россия

E. V. Kuznecova

Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

PhD (Biology), Senior Researcher, Laboratory for the Study of Risk Factors for Influenza and ARVI

St. Petersburg

Россия

V. G. Majorova

Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Senior Researcher, Laboratory for the Study of Risk Factors for Influenza and ARVI

St. Petersburg

Россия

R. A. Kadyrova

Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

Junior Researcher, Laboratory of Cell Cultures

St. Petersburg

Россия

N. I. Lvov

Kirov Military Medical Academy, Ministry of Defence of the Russian Federation

Email: fake@neicon.ru

PhD, MD (Medicine), Assistant Professor, Professor of Department of Infectious Diseases

St. Petersburg

Россия

A. A. Go

St. Petersburg Pasteur Institute

Email: fake@neicon.ru

PhD (Medicine), Infectious Disease Physician, Clinical Diagnostic Department

St. Petersburg

Россия

A. A. Sominina

Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation

Email: fake@neicon.ru

PhD, MD (Medicine), Professor, Head of the Laboratory for the Study of Risk Factors for Influenza and ARVI

St. Petersburg

Россия

References

  1. Изучение популяционного иммунитета к гриппу у населения Российской Федерации: Методические указания МУ 3.1.3490-17 (утв. Главным государственным санитарным врачом РФ 27 октября 2017 г.)
  2. Методы определения показателей качества иммунобиологических препаратов для профилактики и диагностики гриппа: Методические указания МУ 3.3.2.1758-03 (утв. Главным государственным санитарным врачом РФ 28 сентября 2003 г.)
  3. Alvarez M.M., López-Pacheco F., Aguilar-Yañez J.M., Portillo-Lara R., Mendoza-Ochoa G.I., García-Echauri S., Freiden P., Schultz-Cherry S., Zertuche-Guerra M.I.,Bulnes-Abundis D., Salgado-Gallegos J., Elizondo-Montemayor L., Hern á ndezTorre M. Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method. PLoS One, 2010, vol. 5, no. 4: e10176. doi: 10.1371/journal.pone.0010176
  4. Benoit A., Beran J., Devaster J.M., Esen M., Launay O., Leroux-Roels G., McElhaney J.E., Oostvogels L., van Essen G.A., Gaglani M., Jackson L.A., Vesikari T., Legrand C., Tibaldi F., Innis B.L., Dewé W. Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease. Open Forum Infect. Dis., 2015, vol. 2, no. 2: ofv067. doi: 10.1093/ofid/ofv067
  5. Black S., Nicolay U., Vesikari T., Knuf M., Del Giudice G., Della Cioppa G., Tsai T., Clemens R., Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J., 2011, vol. 30, pp. 1081–1085. doi: 10.1097/INF.0b013e3182367662
  6. Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. Morb. Mortal. Wkly. Rep., 2009, vol. 58, no. 19, pp. 521–524.
  7. Ehrlich H.J., Müller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S., Löw-Baselli A., Vartian N., Bobrovsky R., Pavlova B.G., Pöllabauer E.M., Kistner O., Barrett P.N. Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med., 2008, vol. 358, no. 24, pp. 2573–2584. doi: 10.1056/NEJMoa073121
  8. EMA, Guideline on influenza vaccines. Non-clinical and clinical module. Draft. 2016.
  9. Grund S., Adams O., Wählisch S., Schweiger B. Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus. J. Virol. Methods, 2011, vol. 171, no. 2, pp. 369–373. doi: 10.1016/j.jviromet.2010.11.024
  10. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutinatination binhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg., 1972, vol. 70, pp. 767–777.
  11. Lin Y., Gu Y., McCauley J.W. Optimization of a quantitative micro-neutralization assay. J. Vis. Exp., 2016, vol. 118: e54897. doi: 10.3791/54897
  12. Matrosovich M., Gao P., Kawaoka Y. Molecular mechanisms of serum resistance of human influenza H3N2 virus and their involvement in virus adaptation in a new host. J. Virol., 1998, vol. 72, no. 8, pp. 6373–6380.
  13. Memoli M.J., Shaw P.A., Han A., Czajkowski L., Reed S., Athota R., Bristol T., Fargis S., Risos K., Powers J.H., Davey R.T., Taubenberger J.K. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. mBio, 2016, vol. 7, no. 2: e00417-16. doi: 10.1128/mBio.00417-16
  14. Nakane P.K., Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. J. Histochem. Cytochem., 1974, vol. 22, no. 12, pp. 1084–1091. doi: 10.1177/22.12.1084
  15. Potter C.W., Oxford J.S. Determinants of immunity to influenza infection in man. Br. Med. Bull., 1979, vol. 35, pp. 69–75.
  16. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., Fukuda K., Cox N.J., Katz J.M. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol., 1999, vol. 37, pp. 937–943.
  17. Rudenko L., Kiseleva I., Naykhin A.N., Erofeeva M., Stukova M., Donina S., Petukhova G., Pisareva M., Krivitskaya V., Grudinin M., Buzitskaya Zh., Isakova-Sivak I., Kuznetsova S., Larionova N., Desheva J., Dubrovina I., Nikiforova A., Victor J., Neuzil K., Flores J., Tsvetnitsky V., Kiselev O. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS One, 2014, vol. 9, no. 2: е87962. doi: 10.1371/journal.pone.0087962
  18. Serological diagnosis of influenza by microneutralization assay. WHO Manual. 2010.
  19. Stephenson I., Das R.G., Wood J.M., Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine, 2007, vol. 25, no. 20, pp. 4056–4063. PMID: 17412461. doi: 10.1016/j.vaccine.2007.02.039
  20. Stephenson I., Wood J.M., Nicholson K.G., Zambon M.C. Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J. Med. Virol., 2003, vol. 70, pp. 391–398. doi: 10.1002/jmv.10408
  21. Trombetta C.M., Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert. Rev. Vaccines, 2016, vol. 15, no. 8, pp. 967–976. doi: 10.1586/14760584.2016.1164046
  22. Tsang T.K., Cauchemez S., Perera R.A., Freeman G., Fang V.J., Ip D.K., Leung G.M., Malik Peiris J.S, Cowling B.J. Association between antibody titers and protection against influenza virus infection within households. J. Infect. Dis., 2014, vol. 210, no. 5, pp. 684–692. doi: 10.1093/infdis/jiu186
  23. Verschoor C.P., Singh P., Russell M.L., Bowdish D.M., Brewer A., Cyr L., Ward B.J., Loeb M. Correction: Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One, 2015, vol. 10, no. 6: e0131531. doi: 10.1371/journal.pone.0131531
  24. Zhu H., Ding X., Chen X., Yao P., Xu F., Xie R., Yang Z., Liang W., Zhang Y., Li Y., Shen J., He P., Guo Z., Su B., Sun S., Zhu Z. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits. Vaccine, 2011, vol. 29, no. 33, pp. 5421–5423. doi: 10.1016/j.vaccine.2011.05.067

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Krivitskaya V.Z., Kuznecova E.V., Majorova V.G., Kadyrova R.A., Lvov N.I., Go A.A., Sominina A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies